We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F (n = 101), thrombopoietin receptor gene (MPL) (n = 4) or calreticulin (CALR) (n = 31) mutation in peripheral blood on day +100 and +180 after AHSCT. After a median follow-up of 78 months, the 5-year estimated overall survival was 60% (95% confidence interval (CI): 50-70%) and the cumulative incidence of relapse at 5 years was 26% (95% CI: 18-34%) for the entire study population. The percentage of molecular clearance on day 100 was higher in CALRmutated patients (92%) in comparison with MPL-(75%) and JAKV617F-mutated patients (67%). Patients with detectable mutation at day +100 or at day +180 had a significant higher risk of clinical relapse at 5 years than molecular-negative patients (62% vs 10%, P o 0.001) and 70% vs 10%, P o 0.001, respectively) irrespectively of the underlying mutation. In a multivariate analysis, high-risk diseases status (hazard ratio (HR) 2.5; 95% CI: 1.18-5.25, P = 0.016) and detectable MRD at day 180 (HR 8.36, 95% CI: 2.76-25.30, P o 0.001) were significant factors for a higher risk of relapse.
INTRODUCTION
Allogeneic stem cell transplantation can cure a substantial number of patients with myelofibrosis. Relapse is the major case of treatment failure, and depending on disease status and conditioning regimen, it occurs in 10 to 43% of transplanted patients. [1] [2] [3] [4] [5] A small study suggested that donor lymphocyte infusions were less effective at clinical relapse than at the time of minimal residual disease (MRD), 6 indicating that early detection of MRD may be important. As JAK2V617F, 7 myeloproliferative leukemia virus (MPL) 8 and more recently, calreticulin (CALR) mutations 9, 10 are detectable in~80 to 90% of myelofibrosis patients, these mutations may serve as MRD markers after allogeneic stem cell transplantation.
The aim of the study was to evaluate the impact of detectable molecular markers in peripheral blood on day +100 and +180 after SCT on clinical long-term outcome with respect to clinical relapse.
PATIENTS AND METHODS
We screened 154 patients with primary myelofibrosis (PMF (n = 102), post ET/PV myelofibrosis (n = 46), myelofibrosis in transformation or transformed to acute leukemia (n = 5) and unclassifiable myeloproliferative neoplasms (n = 1) for mutational status. We applied JAK2V617F- 11 and MPL-specific quantitative PCRs (sensitivity for both: 0.01%). 12 CALR mutations were identified by next-generation sequencing and confirmed by Sanger sequencing. For CALR type-2 mutation we made use of a novel digital PCR-based assay described elsewhere. 13 In short, a duplex-digital PCR was designed that simultaneously detects the CALR p.K385fs*47 (type-2) mutation and the respective wild-type locus. As shown using serial dilutions and buffy-coat cells from healthy donors, the assay combines high sensitivity (0.02%) with excellent specificity. 13 The JAK2V617F mutation was found in 101 patients, MPL and CALR mutations in 4 and 31 patients, respectively, whereas 13 patients were 'triple negative'. For detection and interpretation of MRD, we excluded 'triple-negative' patients and those who received a second allogeneic transplantation (n = 5) from further analysis. Thus, the presented analysis is based on 136 patients (57 females and 79 males) with a median age of 58 years (range: 32-75) and dynamic International Prognostic Scoring System at transplant of low (n = 2), intermediate-1 (n = 15), intermediate-2 (n = 42) or high risk (n = 69); Lille score was low (n = 20), intermediate (n = 65) and high (n = 25). The donor source was HLA-identical sibling (n = 26), and unrelated donor (n = 110) including mismatched unrelated donors (n = 43). All but two patients received PBSCs. All patients underwent busulfan/ fludarabine-based reduced intensity conditioning before allogeneic stem cell transplantation as reported recently. 1 Patients' characteristics are listed in Table 1 .
Statistical methods
To analyze the impact of residual disease on day +100 and +180 after stem cell transplantation, only those patients who are alive and relapse free with an investigation of the corresponding mutation on days +100 (n = 107) and/or +180 (n = 89) were included. End point was incidence of clinical relapse. Characteristics of patients were expressed as median and range for continuous variables and frequencies for categorical variables. Categorical data were compared using χ 2 test or Fisher's exact test. Survival curves were estimated by the Kaplan-Meier method. The log-rank test was used to estimate the incidence of relapse to account for competing risk. For incidence of relapse, non-relapse mortality after SCT was considered competing events. The Gray test was used to compare the cumulative incidence curves.
Univariate analysis was performed using Fine and Gray proportional hazard model: most calculations were performed using SPSS Version 15 (SPSS, IBM Corp, Armonk, NY, USA); the competing risk analyses were carried out using ACCorD (V Gebski, NHMRC Clinical Trials Center and University of Sydney, Camperdown, NSW, Australia).
RESULTS
After a median follow-up of 78 months (range: 49-101 months) for the entire study population, the estimated survival was 60% (95% CI: 50-70) and the cumulative incidence of relapse at 5 years was 26% (95% CI: 18-34). On days +100 and +180 after stem cell transplantation, 27 and 11% of the patients still had a detectable molecular marker in peripheral blood. The percentage of molecular clearance was higher for CALR-mutated patients (92%) than for MLP-(75%) or JAK2V617F-positive patients (67%). Patients with detectable molecular marker on day +100 had a significantly higher risk of developing clinical relapse at 5 years (62% vs 10%, P o0.001) (Figures 1a and b) . The difference became even more pronounced for patients with detectable marker on day +180 associated with a risk of clinical relapse at 5 years of 70% as compared with 10% in MRD-negative patients (Po 0.001). In a multivariate analysis for relapse beside high-risk disease status (hazard ratio (HR): 2.5; 95% confidence interval (CI): 1.19-5.26, P = 0.016), detectable MRD at day +180 has the highest risk of clinical relapse (HR: 8.37; 95% CI: 2.77-25.30, Po 0.001). The higher risk of relapse for MRD-positive patients at day +180 translated into a significantly worse relapse-free survival at 5 years (70% vs 20%, P o0.001), but not into differences in overall survival at 5 years (78% vs 70%, P = 0.7) (Figures 1c and d) . This might be due to effective salvage treatment for MRDpositive patients who received donor lymphocyte infusion or second transplantation.
14 Whereas we observed a trend for better 5-year overall survival of CALR-and MPL-mutated patients (71 and 75%) in comparison with JAK2-mutated patients (57%, P = 0.48), the risk of relapse at 5 years was similarly low, irrespective of the mutation (P = 0.4), once a patient became negative (Figure 2) .
DISCUSSION
Relapse has become the major cause of treatment failure after allogeneic stem cell transplantation, so as well in patients with myelofibrosis.
1,2 The most likely cause of relapse after allogeneic stem cell transplantation is persistence of MRD. Therefore, detection of MRD after stem cell transplantation may be of importance, especially if intervention for treatment of MRD such as early reduction of immunosuppressive drugs or donor lymphocyte infusion are possible. More recent advance in molecular genetics of myelofibrosis has revealed driver mutations such as JAK2V617F, CALR and MPL, and one of these mutations can be detected in at least 80 to 90% of myelofibrosis patients. In our study, we could confirm this observation and found in~90% of the patients the JAK2V617F or MPL or CALR mutation, which could be used as a MRD marker after allogeneic stem cell transplantation. We could convincingly show if the molecular markers are still detectable either on day +100 or on day +180 after stem cell transplantation; the risk of clinical relapse is significantly higher than in those without detectable MRD. This could be of importance because those MRD may help to reduce immunosuppressive agents or to guide adoptive immunotherapy because a small study suggested higher efficacy and lower risk of GvHD if donor lymphocyte infusion were given at a molecular rather than at a clinical relapse. 6 The impact of persistent JAK2V617F positivity in peripheral blood after allogeneic stem cell transplantation in JAK2-positive myelofibrosis patients was described in smaller studies. 15, 16 Few cases were also reported for CALR-and MPL-positive patients after stem cell transplantation. 17, 18 However, crucial for MRD monitoring after stem cell transplantation is a high sensitivity of the MRD method. While for JAK2V617F and MPL a sensitivity of 10 −5 has been described by PCR technique, 11, 18 the sensitivity of CALR mutation detection by PCR is less sensitive. Here we recently developed a digital PCR with high sensitivity and specificity. 13 Obviously, it would be also useful to detect other molecular markers in the 'triple-negative' patient population, which is considered to be a worse prognostic group of patients. 10 Here novel methods based on next-generation sequencing are currently under investigation, and may also help to monitor most of the triple-negative myelofibrosis patients in the future, but here still some work needs to be done to improve the sensitivity of the method. CONCLUSION JAKV617F, CALR and MPL are valuable molecular markers that can be used in~90% of myelofibrosis patients to monitor MRD after stem cell transplantation. Persistence of molecular disease on days +100 or +180 can guide early tapering of immunosuppressive drugs or adoptive immunotherapy with donor lymphocyte infusions to prevent clinical relapse. 
